LataMed AI Corp. (OTC: LMED), a healthcare technology company focused on Latin America, announced that its mobile healthcare application has entered its final development stage. The company is completing testing, optimization, and deployment preparations ahead of planned availability through the Apple App Store and Google Play. Management expects to submit the app for distribution in the coming weeks, subject to platform review and technical requirements.
This milestone marks a transition from development to public availability, providing users with a convenient mobile access point to LataMed AI's digital healthcare ecosystem. The app is designed to offer a scalable foundation for future functionality, including patient-facing tools, healthcare-provider interaction, digital communications, access to medical information, and healthcare-service coordination.
Mobile accessibility is crucial to LataMed AI's strategy in Latin America, where smartphones are a primary means of accessing digital services. By launching on both major app marketplaces, the company aims to provide users with a direct and accessible way to engage with its healthcare platform. This move supports the company's long-term vision of connecting patients, healthcare professionals, pharmacies, insurers, payment providers, and wellness organizations in an integrated digital environment.
LataMed AI continues to develop artificial intelligence-supported technologies, including CardioAI, PulmoAI, and NeuroAI, which are intended to assist healthcare professionals in evaluating cardiovascular, pulmonary, and neurological health information. The mobile app is expected to serve as an additional pathway for users and professionals to interact with these AI tools, subject to continued development and regulatory requirements.
“Our mobile application is now moving from development toward deployment, and we believe we are approaching an important milestone for LataMed AI,” said Dr. Kevin Rodan Levy, CEO. “Our team is completing the final stages of testing and preparation, and we currently expect the application to become available through the Apple App Store and Google Play in the coming weeks, subject to the applicable platform review processes.”
Dr. Levy added, “Mobile availability is important because it provides a direct connection between users and the digital healthcare ecosystem we are building. Our objective is to create a platform that is practical, accessible, and capable of expanding as we continue introducing additional healthcare services and artificial intelligence-supported tools.”
The anticipated release represents a step toward making LataMed AI's technology more accessible. Following the initial launch, the company intends to evaluate additional functionality and integrations for future versions. Updates will be provided as milestones are completed.
For more information, visit https://latamed.ai or review the company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.
